Too many early drug discovery programs move forward with fragmented evidence: promising biology, uncertain chemistry, incomplete ADME/Tox understanding, and limited translational confidence. Genmap-Pro was created to bring these dimensions together into a single decision framework.
Our approach
We combine computational models, biological interpretation and strategic R&D expertise. Our role is not to replace experiments, but to help teams ask better questions and prioritize the most informative next studies.
In addition to evaluating existing assets, Genmap-Pro can generate AI-designed molecular analogues and rank them through activity, selectivity, ADMET/Tox, Safety Shield 44™ and confidence filters. This allows teams to move from a single molecule or hypothesis toward a broader, prioritized set of experimentally actionable options.
Independence and confidentiality
Genmap-Pro provides an independent, confidential assessment designed to support internal review, board discussions, partnering decisions and due diligence.
Our team
Our team is composed of experienced professionals with complementary backgrounds in pharmaceutical R&D, artificial intelligence, data science, cheminformatics and preclinical development. We bring together scientific rigor, advanced analytics and strategic thinking to help biotech startups and investors make better-informed decisions.
Our philosophy
Genmap-Pro does not treat AI predictions as conclusions. We treat them as structured evidence, interpreted in context, challenged through uncertainty, domain applicability and biological plausibility, then translated into decision-ready recommendations.
